Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

While some of the initial zeal around localized vaccine production in Africa has waned since the height of the COVID-19 pandemic, efforts to bolster the continent’s immunization autonomy—especially | ...

The report provides insights into GSK's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) ...

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

Latest forecasts from the Office for Budget Responsibility (OBR) are thought to show that almost all the headroom has been ...

Find insight on GSK, Novo Nordisk, tariff escalation and more in the latest Market Talks covering Health Care.

GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of products.